论文部分内容阅读
目的:探讨紫杉醇、吉西他滨及多西他赛联合奈达铂对晚期非小细胞肺癌(NSCLC)的疗效。方法:随机将64例晚期NSCLC患者分为紫杉醇组、吉西他滨组及多西他赛组,分别联合奈达铂进行化疗。统计3组治疗有效率及临床受益率、生活质量改善情况、不良反应及随访中位无进展生存期(PFS)。结果:紫杉醇组临床受益率高于吉西他滨组及多西他赛组,差异有统计学意义(P<0.05);3组治疗有效率比较差异无统计学意义(P>0.05)。紫杉醇组生活质量改善率优于吉西他滨组及多西他赛组,差异有统计学意义(P<0.05)。紫杉醇组神经毒性大于其他二组,差异有统计学意义(P<0.05);患者均获随访,紫杉醇组、吉西他滨组及多西他赛组的PFS分别为5.65、4.55及3.50个月(P<0.05)。结论:紫杉醇、吉西他滨及多西他赛联合奈达铂对晚期NSCLC的化疗效果相近,但紫杉醇组可更好地改善患者的生活质量、控制疾病进展,值得临床深入研究。
Objective: To investigate the efficacy of paclitaxel, gemcitabine and docetaxel combined with nedaplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods: Sixty-four patients with advanced NSCLC were randomly divided into paclitaxel group, gemcitabine group and docetaxel group, respectively, combined with nedaplatin for chemotherapy. Three groups of treatment efficiency and clinical benefit rate, quality of life improvement, adverse reactions and follow-up median progression-free survival (PFS) were calculated. Results: The clinical benefit rate of paclitaxel group was higher than that of gemcitabine group and docetaxel group (P <0.05). There was no significant difference between the three groups in the treatment efficiency (P> 0.05). The improvement rate of quality of life in paclitaxel group was superior to gemcitabine group and docetaxel group, the difference was statistically significant (P <0.05). The paclitaxel group had higher neurotoxicity than the other two groups (P <0.05). All patients were followed up. The PFS of paclitaxel group, gemcitabine group and docetaxel group were 5.65, 4.55 and 3.50 months (P < 0.05). Conclusion: Paclitaxel, gemcitabine and docetaxel combined with nedaplatin have similar effects on advanced NSCLC. However, the paclitaxel group can better improve the quality of life of patients and control the progression of the disease, which deserves further study in clinic.